It is evident that the deregulated IL-33/ST2 network affects the progression, metastasis, and the response to therapeutics in different types of cancers, including head and neck squamous cell carcinoma.7,65,88, , –91 Therefore, it has been postulated that immunotherapies against IL-33/ST2 signals by relevant neutralizing antibodies may offer a novel immunotherapeutic strategy for esophageal cancer. The gene discussed is IL33; the disease is head and neck squamous cell carcinoma.